Saint Louis University

A recirculation system for recirculating intestinal content within an intestinal tract of a subject including a recirculation pathway extending from a distal portion of the intestinal tract to a proximal portion of the intestinal tract forming a recirculation loop for recirculating the intestinal content through the proximal portion of the intestinal tract to increase nutrient absorption from the intestinal content. A bypass pathway in fluid communication with the recirculation pathway and configured to divert the intestinal content from the recirculation pathway to continue along the intestinal tract.

The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

Disclosed are therapeutic compositions, methods of preparing, and methods use for the treatment of infectious diseases and cancer. More specifically. Natural Killer Cell (NK Cell)-derived extracellular vesicles (EV's) are demonstrated as potent therapeutic agents that can kill tumor cells in vivo, but do not kill normal cells.

The present disclosure provides inhibitors of microorganisms including viruses and fungi of the formula (I) or (II) wherein the variables are defined herein. Also provided are methods of treatment using these agents in the treatment of infections of microorganisms such as viruses and fungi.

The present disclosure provides compositions and methods for inhibiting T cell senescence and improving T cell immunotherapies. In particular, inhibitors of group IV A phospholipase A2 are disclosed as useful in modulating the lipid metabolism of cells, in particular effector T cells, such that T reg- and tumor cell-induced cell senescence is abrogated. These methods may be employed with particular utility in adoptive T cell therapies and/or enhanced T cell effector functions in vivo, including those performed in combination with checkpoint blockade therapies.

The present disclosure generally relates to systems and methods for guiding surgical tools to a surgical site, and more particularly, to systems and methods for guiding a tool sheath of a delivery system to a surgical site such as a location in a subject's brain and associated surgical procedures.

Disclosed are alginate-specific deoxyribonucleic acid (DNA) aptamers that specifically bind to alginate hydrogels and alginate hydrogels containing alginate-specific DNA aptamers. The alginate-specific DNA aptamers display slower diffusion out of alginate hydrogels and function as anchors for other biomolecules in a wide range of applications.

In one aspect, the present disclosure provides methods of treating a bacterial infection using an inhibitor of the nucleotidyltransferase superfamily enzyme. In some embodiments, the compounds have one of the following formulas (I), (II), (III), or (IV) wherein R 1 , R 2 , and R 3 are as defined herein or a pharmaceutically acceptable salt thereof. The compounds may be used to treat a bacterial infection including an infection of Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter species.

In some aspects, the present disclosure provides germ cell nuclear factor ligands of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions and methods of use thereof. Also provided are cell cultures and cell culture media comprising the GNCF ligands of the present disclosure as well as methods of use thereof.

This application relates to double-stranded small interfering RNAs that modulate DUX4 gene expression and describes methods of inhibiting DUX4 gene expression by contacting a cell with said double-stranded small interfering RNAs. The application further provides compositions comprising said double-stranded small interfering RNAs and their use in methods of preventing or treating a disease or disorder associated with aberrant expression of DUX4, such as facioscapulohumeral muscular dystrophy (FSHD) or cancer, in a subject.